echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Maintenance therapy with rucaparib after chemotherapy in DNA repair-deficient metastatic urothelial carcinoma

    J Clin Oncol: Maintenance therapy with rucaparib after chemotherapy in DNA repair-deficient metastatic urothelial carcinoma

    • Last Update: 2022-08-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A subset of patients with metastatic urothelial carcinoma (mUC) have a DNA repair deficient (DRD) phenotype that predicts benefit from platinum-based chemotherap.


    DRD biomarker-positive mUC patients without cancer progression within 10 weeks of chemotherapy were randomized (1:1) to rucaparib (600 mg twice daily) or placebo and maintained until disease progres.



    Of the 248 patients, 74 (28%) were positive for the DRD biomarker, 40 of whom were randomized into two groups (20 in each group.


    In the safety population (n=39), treatment-related adverse reactions were more or less low-grad.


    In conclusion, maintenance therapy with lucaparib after platinum-based chemotherapy can prolong the progression-free survival of patients with DRD biomarker-positive mUC, and it is well tolerate.


     

    Original source:

    Simon .


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.